Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
DAIC
JULY 29, 2024
Edwards anticipates FDA approval of the JenaValve Trilogy Heart Valve System in late 2025, which will represent the first approved therapy for patients suffering from AR. Building on an investment made in 2016, Edwards has exercised its option to acquire Endotronix , a leader in heart failure (HF) management solutions.
98 
Let's personalize your content